. 2020 Sep; 7:133-142.
doi: 10.2147/JHC.S224938.

Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date

Alison L Raybould 1 Hanna Sanoff 1 
  • PMID: 32984090
  •     31 References
  •     12 citations


For over a decade, sorafenib remained the only systemic agent with proven clinical efficacy for patients with advanced hepatocellular carcinoma (HCC). Recent years have seen a proliferation of agents. In the first line, lenvatinib was found to be non-inferior to sorafenib in terms of overall survival (OS), with significantly better progression-free survival and objective response rate. Meanwhile, encouraging efficacy signals were observed in phase I/II studies of immune checkpoint inhibitors as monotherapy in HCC. Although subsequent phase III trials failed to demonstrate statistically significant benefit in OS, other clinically meaningful outcomes were observed, including long-term disease control with a favorable toxicity profile. In addition, a synergistic response has been postulated based on the interplay between antiangiogenic molecular targeted agents and immunotherapy. On this basis, interest has turned toward combination strategies of immunotherapy with these standard-of-care medications in the hope of improving treatment efficacy for advanced HCC, while maintaining tolerable safety profiles. Indeed, preliminary results from phase I studies of lenvatinib plus pembrolizumab and atezolizumab plus bevacizumab have proved favorable, prompting phase III investigations in the frontline setting, and for atezolizumab plus bevacizumab, these positive findings have been substantiated by recent reporting of phase III data from IMbrave150. In this review, we will present the currently available data on combination therapy atezolizumab plus bevacizumab in advanced HCC, and compare these findings to other promising combination treatments, most notably that of lenvatinib plus pembrolizumab.

Keywords: advanced hepatocellular carcinoma; antiangiogenic treatment; combination therapy; immunotherapy.

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Andrew X Zhu, Yoon-Koo Kang, +22 authors, REACH-2 study investigators.
Lancet Oncol, 2019 Jan 23; 20(2). PMID: 30665869
Highly Cited.
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng, Yoon-Koo Kang, +18 authors, Zhongzhen Guan.
Lancet Oncol, 2008 Dec 20; 10(1). PMID: 19095497
Highly Cited.
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.
Pierce K H Chow, Mihir Gandhi, +39 authors, Asia-Pacific Hepatocellular Carcinoma Trials Group.
J Clin Oncol, 2018 Mar 03; 36(19). PMID: 29498924
Highly Cited.
Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal.
CA Cancer J Clin, 2019 Jan 09; 69(1). PMID: 30620402
Highly Cited.
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model.
Takayuki Kimura, Yu Kato, +10 authors, Kenichi Nomoto.
Cancer Sci, 2018 Nov 18; 109(12). PMID: 30447042    Free PMC article.
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Richard S Finn, Shukui Qin, +19 authors, IMbrave150 Investigators.
N Engl J Med, 2020 May 14; 382(20). PMID: 32402160
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
Masatoshi Kudo, Kazuomi Ueshima, +20 authors, SILIUS study group.
Lancet Gastroenterol Hepatol, 2018 Apr 11; 3(6). PMID: 29631810
Highly Cited.
Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival.
Ahmedin Jemal, Elizabeth M Ward, +13 authors, Hannah K Weir.
J Natl Cancer Inst, 2017 Apr 05; 109(9). PMID: 28376154    Free PMC article.
Highly Cited.
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Kenji Ikeda, Masatoshi Kudo, +9 authors, Hiromitsu Kumada.
J Gastroenterol, 2016 Oct 06; 52(4). PMID: 27704266    Free PMC article.
Highly Cited.
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.
J Bruix, M Sherman, +8 authors, EASL Panel of Experts on HCC.
J Hepatol, 2001 Oct 11; 35(3). PMID: 11592607
Highly Cited.
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.
Ghassan K Abou-Alfa, Qian Shi, +24 authors, Alan P Venook.
JAMA Oncol, 2019 Sep 06; 5(11). PMID: 31486832    Free PMC article.
Update in global trends and aetiology of hepatocellular carcinoma.
Prashanth Rawla, Tagore Sunkara, Pradhyumna Muralidharan, Jeffrey Pradeep Raj.
Contemp Oncol (Pozn), 2018 Nov 21; 22(3). PMID: 30455585    Free PMC article.
Highly Cited. Review.
Sorafenib in advanced hepatocellular carcinoma.
Josep M Llovet, Sergio Ricci, +22 authors, SHARP Investigators Study Group.
N Engl J Med, 2008 Jul 25; 359(4). PMID: 18650514
Highly Cited.
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.
Jorge A Marrero, Masatoshi Kudo, +15 authors, Riccardo Lencioni.
J Hepatol, 2016 Jul 30; 65(6). PMID: 27469901
Highly Cited.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Anthony B El-Khoueiry, Bruno Sangro, +18 authors, Ignacio Melero.
Lancet, 2017 Apr 25; 389(10088). PMID: 28434648    Free PMC article.
Highly Cited.
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Valérie Vilgrain, Helena Pereira, +35 authors, SARAH Trial Group.
Lancet Oncol, 2017 Nov 07; 18(12). PMID: 29107679
Highly Cited.
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X Zhu, Richard S Finn, +19 authors, KEYNOTE-224 investigators.
Lancet Oncol, 2018 Jun 08; 19(7). PMID: 29875066
Highly Cited.
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Philip J Johnson, Shukui Qin, +24 authors, Ann-Lii Cheng.
J Clin Oncol, 2013 Aug 28; 31(28). PMID: 23980084
Highly Cited.
Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy.
Anna R Kwilas, Renee N Donahue, Kwong Y Tsang, James W Hodge.
Cancer Cell Microenviron, 2015 May 26; 2(1). PMID: 26005708    Free PMC article.
Combination Cancer Immunotherapy with Molecular Targeted Agents/Anti-CTLA-4 Antibody for Hepatocellular Carcinoma.
Masatoshi Kudo.
Liver Cancer, 2019 Mar 01; 8(1). PMID: 30815391    Free PMC article.
Modulation of immunity by antiangiogenic molecules in cancer.
Magali Terme, Orianne Colussi, +3 authors, Julien Taieb.
Clin Dev Immunol, 2013 Jan 16; 2012. PMID: 23320019    Free PMC article.
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
Richard S Finn, Baek-Yeol Ryoo, +18 authors, KEYNOTE-240 investigators.
J Clin Oncol, 2019 Dec 04; 38(3). PMID: 31790344
Highly Cited.
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Ghassan K Abou-Alfa, Tim Meyer, +19 authors, Robin K Kelley.
N Engl J Med, 2018 Jul 05; 379(1). PMID: 29972759    Free PMC article.
Highly Cited.
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Yu-Yang Lin, Ching-Ting Tan, +3 authors, Chiun Hsu.
Semin Liver Dis, 2018 Oct 26; 38(4). PMID: 30357775
Systematic Review.
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Masatoshi Kudo, Richard S Finn, +19 authors, Ann-Lii Cheng.
Lancet, 2018 Feb 13; 391(10126). PMID: 29433850
Highly Cited.
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
Calin Cainap, Shukui Qin, +14 authors, Saied El-Nowiem.
J Clin Oncol, 2014 Dec 10; 33(2). PMID: 25488963    Free PMC article.
Highly Cited.
Prognosis of untreated hepatocellular carcinoma.
Edoardo G Giannini, Fabio Farinati, +10 authors, Italian Liver Cancer (ITA.LI.CA) group.
Hepatology, 2014 Sep 23; 61(1). PMID: 25234419
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jordi Bruix, Shukui Qin, +22 authors, RESORCE Investigators.
Lancet, 2016 Dec 10; 389(10064). PMID: 27932229
Highly Cited.
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
Andrew X Zhu, Olivier Rosmorduc, +11 authors, Yoon-Koo Kang.
J Clin Oncol, 2014 Dec 31; 33(6). PMID: 25547503
Highly Cited.
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
Ann-Lii Cheng, Yoon-Koo Kang, +13 authors, Eric Raymond.
J Clin Oncol, 2013 Oct 02; 31(32). PMID: 24081937
Highly Cited.
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Andrew X Zhu, Joon Oh Park, +18 authors, REACH Trial Investigators.
Lancet Oncol, 2015 Jun 23; 16(7). PMID: 26095784
Highly Cited.
The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma.
Bart Vanderborght, Sander Lefere, Hans Van Vlierberghe, Lindsey Devisscher.
Cells, 2020 Nov 05; 9(11). PMID: 33143149    Free PMC article.
Argininosuccinate synthase 1 suppresses tumor progression through activation of PERK/eIF2α/ATF4/CHOP axis in hepatocellular carcinoma.
Sanghwa Kim, Minji Lee, +7 authors, Haeng Ran Seo.
J Exp Clin Cancer Res, 2021 Apr 12; 40(1). PMID: 33838671    Free PMC article.
Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development.
Xin Li, Yaxi Wang, Xin Ye, Ping Liang.
Front Mol Biosci, 2021 May 01; 8. PMID: 33928118    Free PMC article.
Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC.
Alessandro Granito, Sara Marinelli, +4 authors, Francesco Tovoli.
J Hepatocell Carcinoma, 2021 Jun 04; 8. PMID: 34079777    Free PMC article.
Experience with regorafenib in the treatment of hepatocellular carcinoma.
Alessandro Granito, Antonella Forgione, +6 authors, Francesco Tovoli.
Therap Adv Gastroenterol, 2021 Jun 10; 14. PMID: 34104211    Free PMC article.
Inhibiting USP8 overcomes hepatocellular carcinoma resistance via suppressing receptor tyrosine kinases.
Ying Zhu, Jianguo Xu, +4 authors, Wen Xu.
Aging (Albany NY), 2021 Jun 04; 13(11). PMID: 34081623    Free PMC article.
Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.
Brandon Swed, Kara Ryan, +2 authors, Gagandeep Brar.
Medicine (Baltimore), 2021 Jun 24; 100(25). PMID: 34160456    Free PMC article.
A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents.
Yan Gao, Liyang Lyu, +2 authors, Yuanjia Hu.
Int J Med Sci, 2021 Aug 18; 18(14). PMID: 34400877    Free PMC article.
Emerging treatment modalities for systemic therapy in hepatocellular carcinoma.
Xin Qing, Wenjing Xu, +3 authors, Yewei Zhang.
Biomark Res, 2021 Aug 23; 9(1). PMID: 34419152    Free PMC article.
Multiple targeted self-emulsifying compound RGO reveals obvious anti-tumor potential in hepatocellular carcinoma.
Sanxiu He, Shaorong Tian, +10 authors, Tingxiu Xiang.
Mol Ther Oncolytics, 2021 Oct 01; 22. PMID: 34589579    Free PMC article.
Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.
Qi Li, Mengran Cao, +9 authors, Jinzhang Chen.
Front Oncol, 2022 Mar 15; 12. PMID: 35280760    Free PMC article.
Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways.
Piao Zheng, Zhen Huang, +11 authors, Xue-Fei Tian.
World J Gastrointest Oncol, 2022 Mar 24; 14(2). PMID: 35317323    Free PMC article.